UCBJY:OTCMKTS
UCB Unsponsored Belgium ADR
114,46 US$
arrow_downward
−0,87%(−1,01) 1 d
16 okt., 16:00:00 GMT−4 · USD
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för UCBJY …
Öppen
114,95 US$
Högt
115,28 US$
Lågt
114,23 US$
Börsvärde
39,39 md
Genomsn. vol.
53,31 tn
Volym
70,57 tn
52v högst
168,76 US$
52v lägst
110,55 US$
Beta
0,57
Utestående aktier
389,01 mn
Antal anställda
9 tn
Öppen
114,95 US$
Högt
115,28 US$
Lågt
114,23 US$
Börsvärde
39,39 md
Genomsn. vol.
53,31 tn
Volym
70,57 tn
52v högst
168,76 US$
52v lägst
110,55 US$
Beta
0,57
Utestående aktier
389,01 mn
Antal anställda
9 tn
Nyheter och artiklar
Från webbkällor och nyhetspartner
HurBra.se
·
för 2 dagar sedan
USA-börsen 15 oktober 2026: Vård lyfte, AI pressades
https://tech-insider.org/
·
för 13 minuter sedan
Nasdaq Futures Rebound 0.7% as Earnings Week Looms
Seeking Alpha
·
för 5 minuter sedan
S&P 500 Earnings Yield Jumps Over 5%; Sold The EMXC
The New York Times
·
för 50 minuter sedan
On This Day, Oct. 19: In 1987, the stock market crashed.
Profil
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
Om UCB Unsponsored Belgium ADR